Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more
Adalta Ltd (1AD) - Net Assets
Latest net assets as of June 2025: AU$-598.24K AUD
Based on the latest financial reports, Adalta Ltd (1AD) has net assets worth AU$-598.24K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.14 Million) and total liabilities (AU$2.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-598.24K |
| % of Total Assets | -27.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -109.37% |
| 10-Year Change | -105.64% |
| Growth Volatility | 387.78 |
Adalta Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Adalta Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adalta Ltd (2012–2025)
The table below shows the annual net assets of Adalta Ltd from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$-598.24K | -129.46% |
| 2024-06-30 | AU$2.03 Million | +6.31% |
| 2023-06-30 | AU$1.91 Million | -64.49% |
| 2022-06-30 | AU$5.38 Million | -15.78% |
| 2021-06-30 | AU$6.39 Million | +72.51% |
| 2020-06-30 | AU$3.70 Million | -50.58% |
| 2019-06-30 | AU$7.49 Million | +83.94% |
| 2018-06-30 | AU$4.07 Million | -47.42% |
| 2017-06-30 | AU$7.75 Million | -27.04% |
| 2016-06-30 | AU$10.62 Million | +1403.88% |
| 2015-06-30 | AU$705.89K | +308.46% |
| 2014-06-30 | AU$172.82K | -39.13% |
| 2013-06-30 | AU$283.92K | -72.54% |
| 2012-06-30 | AU$1.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adalta Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5202250500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$49.20 Million | % |
| Other Comprehensive Income | AU$2.23 Million | % |
| Total Equity | AU$-598.24K | 100.00% |
Adalta Ltd Competitors by Market Cap
The table below lists competitors of Adalta Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IA Invest Advice Capital Glob
CO:IAIACG
|
$171.92K |
|
COSUMAR
BC:COSUMAR
|
$171.92K |
|
CARDETY (CUX1.SG)
STU:CUX1
|
$172.01K |
|
STANDARD CHARTERED (STD.SG)
STU:STD
|
$172.04K |
|
BYC Co. Pfd. Ltd. Series 1
KQ:001465
|
$171.89K |
|
GP EUROTUNNEL RGPT
MU:TNU3
|
$171.86K |
|
GPGI, Inc.
NYSE:GPGI
|
$171.85K |
|
LAGARDERE SCA N (LAG.SG)
STU:LAG
|
$171.77K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adalta Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,030,446 to -598,244, a change of -2,628,690 (-129.5%).
- Net loss of 4,502,268 reduced equity.
- Share repurchases of 185,714 reduced equity.
- New share issuances of 1,284,282 increased equity.
- Other comprehensive income increased equity by 75,010.
- Other factors increased equity by 700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.50 Million | -752.58% |
| Share Repurchases | AU$185.71K | -31.04% |
| Share Issuances | AU$1.28 Million | +214.68% |
| Other Comprehensive Income | AU$75.01K | +12.54% |
| Other Changes | AU$700.00K | +117.01% |
| Total Change | AU$- | -129.46% |
Book Value vs Market Value Analysis
This analysis compares Adalta Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | AU$0.12 | AU$0.00 | x |
| 2014-06-30 | AU$0.07 | AU$0.00 | x |
| 2015-06-30 | AU$0.29 | AU$0.00 | x |
| 2016-06-30 | AU$0.69 | AU$0.00 | x |
| 2017-06-30 | AU$0.40 | AU$0.00 | x |
| 2018-06-30 | AU$0.19 | AU$0.00 | x |
| 2019-06-30 | AU$0.36 | AU$0.00 | x |
| 2020-06-30 | AU$0.11 | AU$0.00 | x |
| 2021-06-30 | AU$0.13 | AU$0.00 | x |
| 2022-06-30 | AU$0.02 | AU$0.00 | x |
| 2023-06-30 | AU$0.03 | AU$0.00 | x |
| 2024-06-30 | AU$0.02 | AU$0.00 | x |
| 2025-06-30 | AU$0.00 | AU$0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adalta Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -665.02%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-176.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -278.30% | -93.53% | 1.34x | 2.22x | AU$-787.62K |
| 2014 | -722.64% | -167.69% | 1.62x | 2.66x | AU$-1.27 Million |
| 2015 | -185.28% | -147.29% | 0.92x | 1.37x | AU$-1.38 Million |
| 2016 | -10.96% | -157.59% | 0.07x | 1.01x | AU$-2.22 Million |
| 2017 | -36.57% | -157.65% | 0.22x | 1.04x | AU$-3.61 Million |
| 2018 | -94.65% | -190.82% | 0.46x | 1.09x | AU$-4.26 Million |
| 2019 | -79.00% | -167.24% | 0.38x | 1.24x | AU$-6.67 Million |
| 2020 | -162.25% | -156.14% | 0.56x | 1.87x | AU$-6.38 Million |
| 2021 | -88.13% | -141.16% | 0.44x | 1.42x | AU$-6.27 Million |
| 2022 | -112.69% | -219.98% | 0.26x | 1.98x | AU$-6.60 Million |
| 2023 | -253.99% | -139.84% | 0.45x | 4.05x | AU$-5.04 Million |
| 2024 | -265.03% | -309.66% | 0.31x | 2.74x | AU$-5.58 Million |
| 2025 | 0.00% | -665.02% | 0.32x | 0.00x | AU$-4.44 Million |
Industry Comparison
This section compares Adalta Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $35,125,149
- Average return on equity (ROE) among peers: -38.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adalta Ltd (1AD) | AU$-598.24K | -278.30% | N/A | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |